Harnessing the Immune System to Fight Cancer

 

 

Rick Fair, President & CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment joins eHealth Radio & the Cancer Information and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Rick Fair discuss the following:

1. How does CAR-T cancer therapy compare to standard cancer treatments?
2. What are some of the drawbacks to CAR-T Therapy?
3. What is Bellicum doing to address these challenges?
4. What should people keep in mind when thinking about cancer treatment?

Rick Fair is the President and CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment.

Prior to joining Bellicum, Mr. Fair served as the Senior Vice President, Head of Oncology Global Product Strategy at Genentech/Roche, where he led oncology product strategy and global commercialization. He also oversaw the global launch of five new cancer treatments, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine.

Prior to Genentech, Mr. Fair spent nine years at Johnson & Johnson, where he held leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.

 

 

Website: bellicum.com

Social Media Links:
Facebook: facebook.com/pages/Bellicum-Pharmaceuticals-Inc
Twitter: @BellicumPharma